Ionis Pharmaceuticals, once primarily a research and development entity relying on partnerships, took a significant step forward in 2025 by independently launching two innovative medicines. This shift not only underscores the company’s growing capabilities but also sets the stage for an exciting future, especially with further developments anticipated in 2026.
A Surprising Success in Hepatitis B
The launch of Tryngolza coincided with exciting news from a partnership with GSK, where their antisense oligonucleotide bepirovirsen demonstrated a promising functional cure rate in chronic hepatitis B. CEO Brett Monia expressed confidence in the results, noting the potential impact on treatment paradigms. Analysts, while initially skeptical, were quick to acknowledge the significance of the findings presented at the J.P. Morgan Healthcare Conference.
GSK announced that bepirovirsen achieved a statistically significant functional cure rate in a Phase 3 trial. While specific figures were not disclosed, the results surpassed traditional therapies, which typically yield only a 1-3% functional cure rate, compared to the 15-20% seen in this trial. The full details are expected to be revealed at an upcoming liver health conference, with a new drug application slated for submission soon.
Launching New Therapies
In addition to the promising developments in hepatitis B, Ionis successfully launched two products independently in 2025: Dawnzera, aimed at preventing hereditary angioedema attacks, and Tryngolza, targeting familial chylomicronemia syndrome (FCS). The early performance of Tryngolza has been particularly noteworthy, generating approximately $102 million in sales during its initial year.
Analysts are optimistic about Tryngolza’s future, with projections estimating sales could reach $2 billion by 2034. This optimism is bolstered by the data from a recent Phase 3 trial for Tryngolza in severe hypertriglyceridemia (sHTG), which displayed significant reductions in triglyceride levels. Monia highlighted that these results could facilitate broader applications of the treatment.
Competitive Landscape and Pricing Strategy
As Ionis ventures into the more common disease space with sHTG, it faces competition from other biotechs, notably Arrowhead Pharmaceuticals. Arrowhead’s Plozasiran was approved for FCS in late 2025, and upcoming Phase 3 results for sHTG are anticipated this year. Despite this competition, Monia emphasized the unique position Ionis holds in the FCS market, claiming that they effectively created the space and are reaping the rewards.
The pricing strategy for Tryngolza reflects its rare disease designation, set at $595,000. However, Monia assured that costs would decrease as the drug is introduced for more common indications. Preliminary estimates for the sHTG indication suggest a wholesale acquisition cost ranging from $10,000 to $20,000 annually, significantly lower than Arrowhead’s projected pricing.
Promising Developments in Other Therapeutics
Beyond Tryngolza, Ionis is also advancing its pipeline of partnered therapies, including zilganersen, which demonstrated disease-modifying effects in a Phase 3 trial for Alexander disease. This condition has devastating effects, often leading to early childhood mortality. Ionis plans to submit an approval application for zilganersen in the upcoming quarter.
The company has a robust pipeline, with four Phase 3 readouts scheduled for 2026 across various partnerships, including collaborations with major players like AstraZeneca, Roche, and Novartis. This diverse pipeline positions Ionis to continue its growth trajectory.
A Transformative Year Ahead
Reflecting on 2025, Monia described it as a transformative year for Ionis, marked by significant achievements and strategic advancements. With continued momentum expected throughout 2026, he anticipates building on this success. The upcoming earnings report on February 25 will likely provide further insights into the company’s performance and future directions.
Key Takeaways
- Ionis Pharmaceuticals has made a significant shift to independently launching therapeutics, beginning with Tryngolza and Dawnzera in 2025.
-
The Phase 3 trial results for bepirovirsen indicate a promising functional cure for chronic hepatitis B, potentially reshaping treatment options.
-
Analysts project substantial future sales for Tryngolza, with a competitive pricing strategy poised to capture market share in the sHTG arena.
-
Zilganersen is advancing towards approval, highlighting Ionis’ commitment to addressing rare and challenging diseases.
In summary, Ionis Pharmaceuticals is carving out its own path in the biopharmaceutical landscape, demonstrating resilience and innovation. With exciting developments on the horizon, the company is poised for continued success and impact in the healthcare sector.
Read more → www.biospace.com